News | December 26, 2023
Astellas completes acquisition of Propella Therapeutics
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Development services for gene and cell therapies is planned to begin first in 2025
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
His most recent stint was with Danone India as its Managing Director
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
